School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.
Department of Internal Medicine, National Yang-Ming University Hospital, Yilan, Taiwan, ROC.
J Chin Med Assoc. 2020 Aug;83(8):710-711. doi: 10.1097/JCMA.0000000000000338.
The pandemic infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is widely increasing the patients affiliated with coronavirus disease 2019 (COVID-19) from last December of 2019. It is reported that the entry receptor of SARS-CoV-2 has been confirmed to be angiotensin-converting enzyme 2 (ACE2). Notably, whether the ACE-related inhibitors or drugs modulated ACE2 activity in affecting the viral activity and disease severity of SARS-CoV-2 is still an open question. Dipeptidyl peptidase-4 (DDP-4), a well-known anti-diabetic drug, has been widely used to control the glycemic condition in patients with diabetes. In this article, we are focusing on the impact of ACE inhibitors (ACEI) and DPP4 inhibitors used on SARS-CoV-2 activity and discussions about those drugs that may be related to infectious condition of COVID-19 diseases.
自 2019 年 12 月以来，严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的大流行感染使与 2019 年冠状病毒病（COVID-19）相关的患者数量大幅增加。据报道，SARS-CoV-2 的进入受体已被确认为血管紧张素转换酶 2（ACE2）。值得注意的是，ACE 相关抑制剂或药物是否通过调节 ACE2 活性来影响 SARS-CoV-2 的病毒活性和疾病严重程度，这仍然是一个悬而未决的问题。二肽基肽酶-4（DPP-4）是一种众所周知的抗糖尿病药物，已被广泛用于控制糖尿病患者的血糖状况。在本文中，我们重点关注 ACE 抑制剂（ACEI）和 DPP4 抑制剂对 SARS-CoV-2 活性的影响，并讨论可能与 COVID-19 疾病感染状况相关的这些药物。
